PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25707431-0	2015	5-Azacytidine inhibits human rhabdomyosarcoma cell growth by downregulating insulin-like growth factor 2 expression and reactivating the H19 gene product miR-675, which negatively affects insulin-like growth factors and insulin signaling.	Azacitidine	0-13	insulin	Homo sapiens	76-83	
25707431-0	2015	5-Azacytidine inhibits human rhabdomyosarcoma cell growth by downregulating insulin-like growth factor 2 expression and reactivating the H19 gene product miR-675, which negatively affects insulin-like growth factors and insulin signaling.	Azacitidine	0-13	insulin	Homo sapiens	188-195	
1692214-0	1990	Impact of 5-azacytidine on insulin binding and insulin-induced receptor formation in tetrahymena.	Azacitidine	10-23	insulin	Homo sapiens	27-34	
1692214-3	1990	5-azacytidine inhibits insulin binding and the insulin-induced formation of binding sites as well in the cell generation directly involved in interaction, but enhances insulin binding in the daughter cell generations.	Azacitidine	0-13	insulin	Homo sapiens	23-30	
1692214-3	1990	5-azacytidine inhibits insulin binding and the insulin-induced formation of binding sites as well in the cell generation directly involved in interaction, but enhances insulin binding in the daughter cell generations.	Azacitidine	0-13	insulin	Homo sapiens	47-54	
1692214-3	1990	5-azacytidine inhibits insulin binding and the insulin-induced formation of binding sites as well in the cell generation directly involved in interaction, but enhances insulin binding in the daughter cell generations.	Azacitidine	0-13	insulin	Homo sapiens	47-54	
29966534-5	2018	In fact, 2-3 days after starting each 7-day cycle of 5-azacitidine, he reported higher blood glucose levels, requiring an increased dose of self-administered insulin.	Azacitidine	53-66	insulin	Homo sapiens	158-165	
29500792-3	2018	The physiological control of glucose levels can only be restored by replacing the beta-cell mass.We recently developed a new strategy that allows for epigenetic conversion of dermal fibroblasts into insulin-secreting cells (EpiCC), using a brief exposure to the demethylating agent 5-aza-cytidine (5-aza-CR), followed by a pancreatic induction protocol.	Azacitidine	282-296	insulin	Homo sapiens	199-206	
29500792-3	2018	The physiological control of glucose levels can only be restored by replacing the beta-cell mass.We recently developed a new strategy that allows for epigenetic conversion of dermal fibroblasts into insulin-secreting cells (EpiCC), using a brief exposure to the demethylating agent 5-aza-cytidine (5-aza-CR), followed by a pancreatic induction protocol.	Azacitidine	298-306	insulin	Homo sapiens	199-206